Acute pancreatitis in diabetics: a two-year retrospective study in a tertiary care hospital in Peshawar, Pakistan

Zubair Ahmad Khan, MBBS, FCPS, FICS1, Khalid Saifullah Baig2, Zunnoor Ahmad2, Maryam Afridi2

ABSTRACT

Introduction: Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas. After diagnosis the initial management is preferably done in intensive care unit along with 4-6 hourly insulin sliding scale monitoring for hyperglycemia. Individuals with type II DM are more prone to develop AP. Glycosylated hemoglobin (HbA1c) reflects the blood glucose levels of over past two months and daily glucose levels do not affect its levels in the blood.

Objectives: To find out the frequency of acute pancreatitis in diabetic patients both in type 1 and type 2.

Study Design: Cross-sectional, comparative study

Methodology: This was a retrospective cross-sectional, comparative study based on 154 patients with acute pancreatitis in our tertiary care hospital over the duration of two years i.e. from January 2016 to December 2017. The data were entered and coded where necessary and statistically analyzed using SPSS version 20. Descriptive analysis was done to summarize data in the form of percentages and numbers for categorical data while continuous variables were shown by using mean and standard deviation.

Results: The mean age was 48.6 year with a standard deviation of 16.9 years, the total cases were 154 for the duration two years from January 2016 to December 2017. Out of 147 patients, 72 (44.4%) were male and 75 (46.3%) were female. Only 13 (8.8%) out of 154 patients were diabetics. Total serum pancreatic lipase and serum pancreatic amylase levels were significantly higher in non-diabetic subjects as compared to diabetics. Also, high serum lipase levels were seen in slightly more females than males.

Conclusion: The results of our study documented that the prevalence of acute pancreatitis is more common in non-diabetics as compared to diabetics, and those who were diabetic were between 41 to 60 years of age. We recommend further studies in this area to reach a general agreement on the prevalence of acute pancreatitis and factors affecting its prevalence as well as on the relation of diabetes and severity of acute pancreatitis.

Key words: Amylase; Biomarkers; Diabetes mellitus; HbA1C; Intensive Care Unit; Lipase; Pancreatitis; Scoring systems

Citation: Khan ZA, Baig KS, Ahmad Z, Afridi M. Acute pancreatitis in diabetics: a two-year retrospective study in a tertiary care hospital in Peshawar, Pakistan. Anaesthesia, pain & intensive care 2019;23(2):211-216

INTRODUCTION

Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas characterized by a sudden onset of epigastric pain that is typically felt spreading to the back, retching, hiccups, fever, abdominal distention...
acute pancreatitis in diabetics

and nausea however in severe cases it can lead to necrosis, multiple organ failure and eventual death of the patient. After diagnosis the initial management is preferably done in intensive care unit for 48-72 hours which is mainly supportive, 4-6 hourly insulin sliding scale, monitoring for hyperglycemia and upon improvement of scoring system i.e. Ranson’s criteria, the patient is shifted to ward. Pancreas normally secretes serum amylase (normal value around 23-85 U/L) and serum lipase (normal value ranges from 0-160 U/L), with serum amylase and lipase levels of more than 200U/L pancreatitis is suspected. Causes of AP include gallstones, high blood fat levels, trauma, alcoholism, viral infections, infections with parasites drugs and autoimmunity.

In the US, AP caused around 275,000 hospitalizations in 2009 (a rise of more than twice since 1988) and is the most common gastrointestinal reason for hospital admissions in the US. There is a high rate of AP in the fasting population during the Ramadan. The type 2 diabetic cohort has a 2.83-fold (95% CI 2.61–3.06) greater risk of pancreatitis compared with the nondiabetic cohort.

AP commonly comes with transient hyperglycemia. Studies suggest that individuals with type 2 DM are more prone to develop AP. Most of the patients of type 2 diabetes are obese which is a risk factor for hypertriglyceridemia and severe hypertriglyceridemia is a risk factor for AP. Obesity is also associated with gallstones which could get impacted in the ampulla of Vater and lead to AP.

One of the methods to predict the prognosis of the disease is determined by CT scan (CT severity index). If the scan indicates that the pancreas is only mildly swollen, the prognosis is excellent. If the scan shows large areas of destroyed pancreas, the prognosis is usually poor. Acute severe pancreatitis is associated with high morbidity and mortality due to complications like obstruction of bile or pancreatic duct, leakage from the pancreatic duct, pseudocysts, with a risk of rupture, hemorrhage, infection, damage to the pancreas, pleural effusion and splenic vein thrombosis.

Recent advances in diagnostic and therapeutic interventions have led to a decrease in mortality from AP, especially in those with severe, often necrotizing pancreatitis. Deaths in the first two weeks are attributed to a systemic inflammatory response syndrome (SIRS) owing to the release of various cytokines, later complicated by the infection of pancreatic and peripancreatic necrosis and secondary multi-organ failure (MOF). There are many scoring systems for predicting prognosis of severe AP in Intensive Care Units. These systems also contain glucose values, such as the Ranson scoring system, acute physiology and chronic health evaluation II (APACHE-II) and the Glasgow scoring system.

Glycosylated or glycated hemoglobin referred to as HbA1c, reflects the blood glucose levels of over the previous two months and provides information about the degree of long-term blood glucose control. An HbA1c level of < 42 mmol/mol or < 6% is considered normal, 42-47 mmol/mol or 6.0-6.5% is considered prediabetic and 48 mmol/mol and ≥ 6.5% (cut off for our study) is considered diabetic. An increase in HbA1c levels shows poor diabetic control over long periods of time. This indicator predicts poorer clinical prognosis in patients with AP.

We conducted this study to find out the frequency of AP in patients known to have diabetes either type 1 or type 2.

METHODOLOGY

This was a retrospective cross-sectional comparative study based on 154 patients with AP in our tertiary care hospital at Peshawar (Pakistan) over the duration of two years i.e. from January 2016 to December 2017. All the patients were initially admitted for moderate to severe acute epigastric pain. Further investigations were done at the time of admission to confirm the diagnosis as AP, including serum amylase and serum lipase levels, x-ray chest and abdomen, and CT scan abdomen (CT severity index). All the patients were included in the study regardless of their gender or age and all the non-diabetic and prediabetic patients were excluded from the study. Patients with a previous history of diabetes or with HbA1c ≥ 6·5% were identified as having AP with diabetes (APD), while patients without a history of diabetes and in whom the HbA1c was not higher than 6·5% were considered as AP only and were excluded from the study. The cut off values for both serum amylase and serum lipase to diagnose the case as AP were taken as 160 U/L. All those having values below 160 U/L were also excluded from our study.

The data was entered and coded where necessary and statistically analyzed using SPSS version 20. Descriptive analysis was done to summarize data in the form of percentages and numbers for categorical data while continuous variables were shown by using mean and standard deviation.

RESULTS

The mean age of the patients was 48.6 ± 16.9 y. Total cases studied were 154 reporting during two years from January 2016 to December 2017. Seven patients were excluded sue to one or more reasons. Out of the remaining 147 patients, 72 (44.4%) were male and 75 (46.3%) were female.

Patients with a previous history of diabetes or with HbA1c ≥ 6·5% were identified as having AP with
Table 1: Serum amylase levels in diabetic & non-diabetic patients

<table>
<thead>
<tr>
<th>Patient specifications</th>
<th>Age group (y)</th>
<th>Serum amylase levels (U/L)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41-60</td>
<td>2</td>
<td>1 1 3</td>
<td>7</td>
</tr>
<tr>
<td>61-80</td>
<td>1</td>
<td>0 0 0</td>
<td>1</td>
</tr>
<tr>
<td>Non Diabetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-20</td>
<td>3</td>
<td>1 1 0</td>
<td>7</td>
</tr>
<tr>
<td>21-40</td>
<td>11</td>
<td>2 1 0</td>
<td>21</td>
</tr>
<tr>
<td>41-60</td>
<td>21</td>
<td>4 1 1</td>
<td>41</td>
</tr>
<tr>
<td>61-80</td>
<td>3</td>
<td>1 0 0</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>42</td>
<td>13 11 7 6 2 1 2</td>
<td>89</td>
</tr>
</tbody>
</table>

Table 2: Serum lipase levels in diabetic and non-diabetic patients

<table>
<thead>
<tr>
<th>Patient specifications</th>
<th>Age group (y)</th>
<th>Serum lipase levels (U/L)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41 - 60</td>
<td>1</td>
<td>1 1 1</td>
<td>3</td>
</tr>
<tr>
<td>0 - 20</td>
<td>0</td>
<td>0 0 1</td>
<td>4</td>
</tr>
<tr>
<td>21 - 40</td>
<td>7</td>
<td>2 0 2</td>
<td>14</td>
</tr>
<tr>
<td>Non Diabetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41 - 60</td>
<td>11</td>
<td>8 0 1</td>
<td>27</td>
</tr>
<tr>
<td>61 - 80</td>
<td>8</td>
<td>3 1 0</td>
<td>14</td>
</tr>
<tr>
<td>81 - 100</td>
<td>1</td>
<td>0 0 0</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>27</td>
<td>14 6 4 2 4 2 3 1</td>
<td>63</td>
</tr>
</tbody>
</table>

Table 3: Gender wise distribution of serum amylase

<table>
<thead>
<tr>
<th>Patient specification</th>
<th>Gender</th>
<th>Serum amylase levels (U/L)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic</td>
<td>Male</td>
<td>0 0 0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>0 1 3</td>
<td>7</td>
</tr>
<tr>
<td>Non-diabetic</td>
<td>Male</td>
<td>20 8 2 1 1 1 0 1</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>19 5 3 3 2 1 1 1</td>
<td>39</td>
</tr>
<tr>
<td>Total</td>
<td>42</td>
<td>13 11 7 5 6 2 1 2</td>
<td>89</td>
</tr>
</tbody>
</table>

Table 4: Gender wise distribution of serum lipase

<table>
<thead>
<tr>
<th>Patient specs</th>
<th>Gender</th>
<th>Serum lipase levels (U/L)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic</td>
<td>Female</td>
<td>1 1 1</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>15 5 3 1 1 1 2 0</td>
<td>31</td>
</tr>
<tr>
<td>Non-diabetic</td>
<td>Female</td>
<td>12 8 2 1 1 1 1 1</td>
<td>29</td>
</tr>
<tr>
<td>Total</td>
<td>27</td>
<td>14 6 4 2 4 2 3 1</td>
<td>63</td>
</tr>
</tbody>
</table>
acute pancreatitis in diabetics
diabetes (APD), while patients without a history of
diabetes and in whom the HbA1c was not higher than
6.5% were considered as AP only. The cut off value
for both serum amylose and serum lipase to diagnose
the case as AP was taken as 160 U/L. All those having
values below 160 U/L were also excluded from our
study.

The most common age group of patients was 41-60
y, with overall male preponderance. The highest
detected range of serum amylose (2560-2860 U/L)
was found in just two patients, one diabetic and one
non diabetic. Majority of the patients was having
serum amylose levels in the range of 160-460 U/L i.e.
42 patients. The most common presenting values of
serum lipase were in the range of 161-460 U/L i.e. 27
patients. The highest range of serum lipase (2561-
2860) had only one patient. Most common age group
with raised serum Lipase levels was between 41-60
years of age, 30 in total with 27 non diabetic and 3
diabetic patients.

Serum total amylose levels in diabetics and non-
diabetics of various age groups are shown in Table 1.
Normal serum amylose levels range from 23-85 U/L
while in some labs range goes up to 140 U/L. Table 1
shows all the subjects having higher serum amylose
levels than normal. A total number of subjects which
was recorded to be 7 in 0-20 age group with diabetes
were equal to the number of subjects of the same age
group without diabetes having high serum amylose
than normal. Also, there was no significant difference
between the number of subjects which was recorded
to be 21 in 21-40 age group, diabetic and non-diabetic,
having high serum amylose levels.

In 41-60 age group of diabetics the serum amylose
levels were recorded to be high in 7 subjects,
comparatively, the 41-60 age group of nondiabetics
had significantly more subjects i.e. 41 having high
serum amylose levels. There was a significant
difference in the total number of subjects in 61-80 age
group having diabetes and those not having it with
high serum amylose levels. Only 1 diabetic subject
was recorded to have high serum amylose in 61-80 age
group. While 11 non-diabetic subjects are recorded
to have high serum amylose levels. Thus, in non-
diabetic subjects with the increase in age there is a
significant increase in the number of subjects having
high serum amylose levels but after the age of 60,
there is a significant decrease in the subjects.

Serum total lipase levels in diabetics and non-
diabetics of various age groups are shown in Table 2.
Normal serum lipase levels range from 0-160 U/L.
Total of 63 subjects of different age groups with high
serum lipase levels were divided into diabetics and
non-diabetics (Table 2). Thus, according to this table,
the results reveal that significantly high number of
subjects are non-diabetic having high serum lipase
levels. Also, the number of subjects with high serum
amylose levels increase from 0-20 to 41-60 age groups.
From 61-80 age group onwards the number of subjects
decreased.

Total serum amylose levels were computed separately
for men and women, and are shown in Table 3. There
were a total of 89 subjects, in which, 43(48.3%) were
males and 46(51.6%) were females. Both the genders
were divided into diabetics and non-diabetics. In
a total of 8 diabetic subjects, 1(12.5%) male and
7(87.5%) females had high serum amylose levels.
While in a total of 81 nondiabetic subjects, 42(51.8%)
males and 39(48.1%) females had high serum amylose
levels. Total amylose levels were significantly higher
in non-diabetic subjects as compared to diabetics.
Also, high serum amylose levels were seen in more
females than males.

Serum total lipase levels were separately computed
for males and females, and are shown in Table 4. There
were a total of 63 subjects, in which, 31 were
males and 32 were females. Both the genders were
devided into diabetics and non-diabetics. In a total
of 3 diabetic subjects, there were no males and all
the 3 subjects were females having high serum lipase
levels. While in a total of 60 non-diabetic subjects, 31
males and 29 females had high serum lipase levels.
Total serum lipase levels were significantly higher in
non-diabetic subjects as compared to diabetics. Also,
high serum lipase levels were seen in slightly more
females than males.

DISCUSSION

The most susceptible mean age found in our study
was 48.6 ± 16.9 y, while that in another study16
done by a Pakistani researcher Saaq was 44 ± 17
y. In another study11 done in a tertiary hospital in
Jamaica, the mean age was 45.68 ± 19.64 y. Our study
found that AP is slightly more common in females
than in males i.e. 51% in female and 49% in males.
Another study showed that there were 58% males
and 42% females which were almost similar results.18

The most common range found in AP was 161-460
mg/dl, whereas some other researchers19 found the
levels to be >300 mg/dl. Only 2% of patients had serum amylose levels more
than 2200 mg/dl. A research group found the serum lipase
levels to be > 570 mg/dl,19 but our study found that
the most common range found in AP was 161-460
mg/dl followed by 461-760 mg/dl. We found that the
prevalence of diabetics diagnosed with AP was 8%
which is in accordance with 12.8% in a study done
by Saaq.16 The age groups from 0-40 years had no
diabetic patients in them, between 41-60 years of age
most of the diabetics were found i.e. 69.23%. Other
researchers found the prevalence of 47.1% in the age
group of 45-64.20 Another study done by Urushihara
H and co-workers used a Japanese hospital database
where the age group 60-79 y had a prevalence of 55.8%.\textsuperscript{21} Most of the diabetic patients with AP were females i.e. 84.61% which is in contrast with the 26% prevalence in females done in a study\textsuperscript{1} by Kikuta K and co-workers.

**CONCLUSION**

Our study showed that serum pancreatic lipase is a more accurate biomarker than serum pancreatic amylase in our setting, with almost negligible male to female preponderance. It was also documented that the prevalence of acute pancreatitis is more common in non-diabetics as compared to diabetics.

The most common age group for developing acute pancreatitis in diabetics is 41-60 according to our study. We recommend further studies in this region to reach a general agreement on the frequency of acute pancreatitis and factors affecting it, as well as on the relationship of diabetes and severity of acute pancreatitis.

Conflict of interest: Nil

Authors' contribution:

ZAK; Data Collection, Concept, Data Analysis and Overall Supervision
KSB; Data Interpretation and Manuscript Writing
ZA; Literature Review
MA; Data Tabulation
acute pancreatitis in diabetics

REFERENCES


★ ★ ★ ★ ★